Molecular Pathology and Genomics Core

分子病理学和基因组学核心

• 批准号: 10005248
• 负责人: JON C. ASTER
• 金额: $ 25.18万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10005248
• 关键词: Academic Medical Centers; Address; BCL1 Oncogene; BCL2 gene; Biological Markers; Boston; CLIA certified; Cancer Center; Cells; Cities; Classification; Collection; Color; Complement; Consensus; DNA; Dana-Farber Cancer Institute; Data; Data Analyses; Development; Diagnosis; Diagnostic; Equipment; Evaluation; Formalin; Functional disorder; Genes; Genomics; Genotype; Hematologic Neoplasms; Hematopathology; Histology; Histopathology; Hospitals; Human; IL2RA gene; Immune; Immune response; Immunofluorescence Immunologic; In Situ; Institution; International; Knowledge; Link; Lymphoma; MCL1 gene; MDM2 gene; Medical Genetics; Memorial Sloan-Kettering Cancer Center; Modeling; Mus; Mutate; Normal tissue morphology; North Carolina; Paraffin Embedding; Pathologic; Pathologist; Pathology; Periodicity; Peripheral; Primary Neoplasm; Protocols documentation; Research; Research Personnel; Resistance; Resource Sharing; Resources; STAT5B gene; Sampling; Services; Site; Slide; Stains; System; Systems Analysis; T-Cell Lymphoma; TP53 gene; Testing; Tissue Embedding; Universities; Woman; base; cohort; data analysis pipeline; driver mutation; experience; genomic data; imaging platform; innovation; liquid crystal polymer; molecular pathology; mouse model; neoplastic cell; novel; novel therapeutics; performance site; programs; reagent standard; response; success; targeted exome sequencing; therapeutic target; tumor microenvironment; web interface; web site; working group

PROJECT SUMMARY Core C provides access to specialized professional and technical pathology services and genomic services that are essential to the success of the Program. It does so by carrying out 3 overarching aims that support all three P01 Projects: 1) provide pathology expertise needed for classification of primary human PTCLs and PDX and murine PTCL models; 2) perform standard and novel in situ tests for biomarkers relevant to understanding PTCL pathophysiology and its response and resistance to novel therapies; and 3) perform targeted exome sequencing of a large cohort of well-characterized human PTCLs. The Core delivers these services at two performance sites, one in Boston led by Jon Aster, which will deliver services supporting Aims 1 and 2, and the second in North Carolina led by Sandeep Dave, which will deliver services supporting Aims 1 and 3. Delivery of Aim 1 services relies on the Core's co-leader, Dr. Jon Aster, who is a practicing academic hematopathologist with >25 years of experience with human and murine hematopathology, and is supplemented by additional expertise in Project 1 (John Chan) and access to the Hematologic Malignancies Research Consortium, which includes >25 institutions and has accrued over 1800 cases of T cell lymphomas, a majority with paired normal tissue. Aim 2 services will be provided in Boston include standard histology and immunohistology services and innovative, multiparametric immunofluorescence staining platforms, the Perkin- Elmer Vectra platform and CyCIF is an iterative imaging platform that allows for evaluation of >50 different markers on single FFPE slides. Aim 3 services are delivered at the North Carolina performance site by performing targeted exome sequencing on 410 genes that are frequently mutated in lymphoma, initially using DNA prepared from a cohort of 1833 PTCLs and paired normal tissue controls.

项目总结